about
Interventions for treating acute bleeding episodes in people with acquired hemophilia AInterventions for treating acute bleeding episodes in people with acquired hemophiliaRole of prothrombin complex concentrate in perioperative coagulation therapyProthrombin Complex Concentrates for Bleeding in the Perioperative Setting.Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IXA zymogen-like factor Xa variant corrects the coagulation defect in hemophiliaZymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitroAcquired hemophilia A: emerging treatment options.Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Inhibitor development in haemophilia B: an orphan disease in need of attention.Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.When should prophylaxis therapy in inhibitor patients be considered?Clinical advances in hemophilia management.Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.Reversal of antithrombotic agents.Successful management of a possible antibiotic-related acquired factor V inhibitor: a case report and review of the literature.Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy.Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesNovel therapeutic approaches for haemophilia.Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.Safety and Effectiveness of Factor VIII Inhibitor Bypassing Activity (FEIBA) and Fresh Frozen Plasma in Oral Anticoagulant-Associated Intracranial Hemorrhage: A Retrospective Analysis.Perioperative Coagulation Management of a Hemophilia A Patient During Cardiac Surgery.Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.Life-threatening hemorrhage from acquired hemophilia A as a presenting manifestation of prostate cancer.Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.Management of bleeding in patients taking FXa and FIIa inhibitors.Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding.Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay.Phenotypic variability in a family with haemophilia B and prothrombin G20210A.Bioengineered factor Xa as a potential new strategy for hemophilia therapy.Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII.Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
P2860
Q24194263-6A925C32-1066-4CD7-994F-C32D624FD759Q24197921-B2264DE4-F812-457C-A083-18EEE8FEBD9CQ26863536-03B9BEA0-17AF-4C1F-8EC0-80BC0D3BA87FQ33430766-7758F6EA-B100-4744-9C04-62C139B8B08AQ33608230-EA680701-EA7F-4CC2-836D-13947621E058Q34149960-A9B3FC4C-6A18-45C1-96E4-981216FEA87DQ34568888-F5A07B32-A375-411A-8005-DB83E1203DDDQ35605896-95109473-60F1-4523-B6A8-4D4530826918Q35779980-B0034F04-AFAB-4DCF-A43E-6F6F0BAF82CDQ36480548-B37DBB63-B6A4-4ECC-9456-22BE5C25ECC1Q36872038-7B61BACE-258E-4590-8E82-22AC23F4FD08Q36981731-39F55C7F-F3FE-4B1D-B79C-89503F5AED17Q37552621-C0D59F75-409C-4AB5-8D80-5AD685A6E545Q37854874-A0867EBF-6E87-45E3-BA0C-E1AE7FB30315Q37900933-5A6CDF1D-3846-4A85-9975-041194A45A0AQ37927122-BAB913E5-2718-42BE-B1EF-B89C86592662Q37998377-5E1C7637-D784-4FF0-8862-4BD46A9F16D7Q38069047-92F5274F-827A-4E56-B86F-8B6EFD20284DQ38175956-7E7F75CB-0107-4D53-8745-CC40841F7707Q38235951-E7263406-0E73-404B-BD4C-5C8E3F0F1A61Q38293116-63226274-D923-45CB-A090-1B2088725941Q38513393-EC00956F-FC8C-4696-A604-7EA6FAF68B42Q38660256-09773895-99B7-47FD-A226-007C83EC1B25Q38937992-721CBFDD-CB5C-430F-BD91-7D48EEAB5748Q39227116-10FBCF0D-468F-4D0B-B9BF-6B667D6A58FBQ39995569-4FC230BF-43F8-4DD4-8B06-4B46C27D21F8Q40719779-870B9FB3-37C1-4B55-9C9D-64E301CC927CQ40972656-3CFA703B-F795-48EC-AFA3-566814B0E604Q41947735-BA5F6E66-423D-46FA-A91A-816127BA7C84Q41947739-C4871B6E-5DFE-4ABC-9A5B-FDD6BBB55D5CQ42396736-E1E48B28-3090-416E-BEEB-674D6CC094F4Q42776949-000E7A1C-1E6E-45A0-A0E9-CE993914EFEFQ45007433-98D22DE4-1C2A-45EE-BD4C-C85891E1AF6EQ45863189-E8D992FC-5455-4060-890E-077B0B746CBAQ45871315-6AD08F3E-0172-4E21-AFFC-61F40633DFF5Q45873884-E85DA999-1BC4-49BD-9BDB-13878F1B8397Q45878341-43EAD55A-0493-4800-B1B3-53FAE73B76DCQ45881290-9815EF24-1F75-49F6-9A82-FC90B79EC957Q45882018-77310BA9-71C0-47F7-A05E-314108894B3AQ45886430-1C34B89F-1B2E-4FF0-A4A9-432B657D123F
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
FEIBA: mode of action.
@ast
FEIBA: mode of action.
@en
type
label
FEIBA: mode of action.
@ast
FEIBA: mode of action.
@en
prefLabel
FEIBA: mode of action.
@ast
FEIBA: mode of action.
@en
P2093
P2860
P1433
P1476
FEIBA: mode of action.
@en
P2093
H P Schwarz
P L Turecek
P2860
P356
10.1111/J.1365-2516.2004.00934.X
P478
10 Suppl 2
P577
2004-09-01T00:00:00Z